Although there have been no recent approvals of oral JAK inhibitors (JAK-i) for atopic dermatitis (AD), some interesting study findings have been published. These shed light on the safety of baricitinib, abrocitinib and upadacitinib with reference to the EMA opinion on JAK-i issued some time ago. In the EU, baricitinib has now been given an extended indication for AD patients aged 2 years and older.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
You May Also Like
- Cannabis - medical vs. non-medical use
Interim assessment: the boundaries are fluid
- Case Report
Cutaneous myiasis caused by botfly larvae
- Chronic insomnia, REM sleep instability and emotional dysregulation
Risk factors for anxiety and depression
- Immune sensors
Dysfunctional signaling pathways in cardiomyocytes and their role in heart disease
- Inoperable NSCLC
Efficacy of pembrolizumab in combination with concurrent chemoradiotherapy
- Dementia
Recognize incipient progression and identify countermeasures
- Subtype-specific risks and implications for neurological care
Suicidal tendencies in dementia
- Study report: Hidradenitis suppurativa